Kazutsune Yamagata

Toyoake, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications

Identification of an Intracellular Role for Complement Factor D: Lipid Droplet Biogenesis in Differentiating Adipocytes.

Identification of an Intracellular Role for Complement Factor D: Lipid Droplet Biogenesis in Differentiating Adipocytes.

Journal: Comprehensive Physiology
Published: August 29, 2025

CTCF Is Essential for the Development and Maintenance of CALM-AF10-Induced Leukemia.

CTCF Is Essential for the Development and Maintenance of CALM-AF10-Induced Leukemia.

Journal: Cancer science
Published: December 27, 2024

Loss of NOL10 leads to impaired disease progression of NUP98::DDX10 leukemia.

Loss of NOL10 leads to impaired disease progression of NUP98::DDX10 leukemia.

Journal: Leukemia
Published: January 25, 2024

Genetic and chemical targeting of the ATPase complex TIP48 and 49 impairs acute myeloid leukemia.

Genetic and chemical targeting of the ATPase complex TIP48 and 49 impairs acute myeloid leukemia.

Journal: Leukemia
Published: January 30, 2023

Dual inhibition of EZH1/2 induces cell cycle arrest of B cell acute lymphoblastic leukemia cells through upregulation of CDKN1C and TP53INP1.

Dual inhibition of EZH1/2 induces cell cycle arrest of B cell acute lymphoblastic leukemia cells through upregulation of CDKN1C and TP53INP1.

Journal: International journal of hematology
Published: June 14, 2022

Dual targeting of EZH1 and EZH2 for the treatment of malignant rhabdoid tumors.

Dual targeting of EZH1 and EZH2 for the treatment of malignant rhabdoid tumors.

Journal: Molecular therapy oncolytics
Published: January 19, 2022

CDKN1C-mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib.

CDKN1C-mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib.

Journal: Cancer science
Published: November 10, 2020

MOZ is critical for the development of MOZ/MLL fusion-induced leukemia through regulation of Hoxa9/Meis1 expression.

MOZ is critical for the development of MOZ/MLL fusion-induced leukemia through regulation of Hoxa9/Meis1 expression.

Journal: Blood advances
Published: September 28, 2020

Tip60 activates Hoxa9 and Meis1 expression through acetylation of H2A.Z, promoting MLL-AF10 and MLL-ENL acute myeloid leukemia.

Tip60 activates Hoxa9 and Meis1 expression through acetylation of H2A.Z, promoting MLL-AF10 and MLL-ENL acute myeloid leukemia.

Journal: Leukemia
Published: August 13, 2020

Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma.

Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma.

Journal: Oncogene
Published: December 20, 2018

A Potent Blood-Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft Model.

A Potent Blood-Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft Model.

Journal: Molecular cancer therapeutics
Published: December 06, 2018

Dual inhibition of enhancer of zeste homolog 1/2 overactivates WNT signaling to deplete cancer stem cells in multiple myeloma.

Dual inhibition of enhancer of zeste homolog 1/2 overactivates WNT signaling to deplete cancer stem cells in multiple myeloma.

Journal: Cancer science
Published: August 09, 2018
Showing 1-12 of 19

Last Updated: 09/26/2026